Pharma Tech

EC approves AbbVie’s Tepkinly combination for follicular lymphoma

Jul 7, 2026, 8:54 AM

Read Full Article → EC approves AbbVie’s Tepkinly combination for follicular lymphoma

Translate article text

Choose a language and wait for the translated text.

The EC has granted marketing authorisation for AbbVie’s Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.